Antonia SJ, Borghaei H, Ramalingam SS, et al. - Four clinical studies of nivolumab in 664 patients with formerly treated non-small cell lung cancer (NSCLC; CheckMate 017, 057, 063, and 003) were pooled by researchers to assess the long-term advantage of nivolumab and the impact of response and disease control on subsequent survival. The 4-year overall survival rates with nivolumab were 14%, 19%, and 11% for all patients, those with at least 1% PD-L1 expression, and for those with less than 1% PD-L1 expression, respectively. In CheckMate 017 and 057, 4-year overall survival was 14% in patients treated with nivolumab vs 5% in patients treated with docetaxel. Survival following response at 6 months on nivolumab or docetaxel was longer than following progressive disease at 6 months. Patients with advanced NSCLC treated with nivolumab accomplished a higher term of response vs patients treated with docetaxel, which was related to a long-term survival benefit.